Supplementary file

To detect rs879922 and rs2285666, a real-time PCR was conducted using TaqMan Genotyping Master Mix (Thermo Fisher Scientific, Waltham, USA) and TaqMan™ SNP Genotyping Assay (Thermo Fisher Scientific, Waltham, USA). Polymerase was activated at 95°C for 10 min, then 40 cycles were performed at 95°C for 15 s (denaturing stage), subsequently 60°C for 1 min (annealing) and 60°C for 1 min (elongation). The entire procedure including endpoint genotyping was performed with a use of the LightCycler® 480 System (Roche Diagnostics, Rotkreuz, Switzerland).

Genotyping of rs1978124 was based on PCR amplification with the use of Color Perpetual Taq PCR Master Mix (EURx, Gdansk, Poland). Its primers were synthesized by Genomed (Warsaw, Poland), sorward one: 5' TTGTGTTAAGATCTTGTCCC 3' and reverse: 5'AATAAACTGAGCTCCAGC 3'. After initial denaturation at 94°C for 3 min, 40 cycles were performed at 94°C for 20 s (denaturing stage), then 60.5°C for 30 s (annealing), 72°C for 60 s (elongation), and 72°C for 7 min (final elongation). PCR products were digested by AvaII at 37°C for 16 h. The fragments of 471 bp (allele A) and 305 + 166 bp (allele G), were separated after electrophoresis on 2% agarose gel stained with SimplySafe (EURx, Gdansk, Poland).

Supplementary Table S1.

	rs879922				rs2285666					rs1978124		
	CC	CG	GG	*p*-value	GG	GA	AA	*p*-value	AA	AG	GG	*p*-value
SSc subtype												
- limited	11 (92%)	29 (94%)	13 (76%)	0.24*	35 (95%)	16 (76%)	2	0.12*	30 (86%)	22 (92%)	1 (100%)	0.73*
- diffuse	1 (8%)	2 (6%)	4 (24%)		2 (5%)	5 (24%)	-		5 (14%)	2 (8%)	-	
ANA												
- ACA	6 (50%)	8 (26%)	3 (18%)	0.16*	11 (30%)	6 (29%)	-	0.77*	12 (34%)	5 (21%)	-	0.49*
- Scl70	4 (33%)	20 (64%)	9 (53%)		20 (54%)	12 (57%)	1 (50%)		19 (54%)	13 (54%)	1 (100%)	
- other	2 (17%)	3 (10%)	5 (29%)		6 (16%)	3 (14%)	1 (50%)		4 (12%)	6 (25%)	-	
onset of RP												
- early	7 (58%)	22 (71%)	13 (76%)	0.57	23 (62%)	17 (81%)	2 (100%)	0.014*	26 (74%)	16 (67%)	-	0.28*
- late	5 (42%)	9 (29%)	4 (24%)		24 (38%)	4 (19%)	-		9 (26%)	8 (33%)	1 (100%)	
onset of SSc												
- early	6 (50%)	19 (61%)	12 (71%)	0.53	20 (54%)	15 (71)	2 (100%)	0.32*	24 (69%)	13 (54%)	-	0.17*
- late	6 (50%)	12 (39%)	5 (29%)		17 (46%)	6 (29%)	-		11 (31%)	11 (46%)	1 (100%)	
ILD	5 (42%)	15 (48%)	12 (71%)	0.22	19 (51%)	11 (52%)	2 (100%)	0.63*	16 (46%)	15 (62%)	1 (100%)	0.24*
trophic lesions	4 (33%)	16 (52%)	9 (53%)	0.51	19 (51%)	10 (48%)	-	0.58*	13 (37%)	16 (67%)	-	0.03*
KI	5 (24%)	4 (13%)	7 (24%)	0.48	14 (25%)	1 (5%)	1 (25%)	0.097*	12 (24%)	3 (13%)	1 (17%)	0.56*
CVS disorders	10 (83%)	20 (65%)	9 (53%)	0.24	29 (78%)	9 (43%)	1 (50%)	0.01*	23 (66%)	15 (62%)	1 (100%)	1.0*
cardiac arrythmia	3 (25%)	12 (39%)	6 (35%)	0.7	12 (32%)	9 (43%)	-	0.54*	13 (37%)	8 (33%)	-	0.86*
AH	9 (75%)	14 (45%)	3 (18%)	0.009	20 (54%)	5 (24%)	1 (50%)	0.042*	15 (43%)	10 (42%)	1 (100%)	0.77*
PAH	-	1 (3%)	2 (12%)	0.29*	2 (5%)	21 (100%)	1 (50%)	0.008*	2 (6%)	1 (4%)	-	1.0*
GI	7 (58%)	17 (55%)	6 (35%)	0.35	23 (62%)	7 (33%)	-	0.041*	15 (43%)	15 (62%)	-	0.19*
JI	1 (8%)	13 (42%)	10 (59%)	0.02	17 (46%)	6 (29%)	1 (50%)	0.38*	11 (31%)	12 (50%)	1 (100%)	0.14*
ACE2	0.107	0.084	0.049	0.14**	0.078	0.074	0.141	0.79**	0.09	0.031		0.005**

*Fisher exact test; **ANOVA Kruskal-Wallis.

SSc: systemic sclerosis; ANA: antinuclear antibodies; ACA: anticentromeric; Scl70: anti-topoisomerase I; RP: Raynaud's phenomenon; ILD: interstitial lung disease; KI: kidney involvement; CVS: cardiovascular; AH: arterial hypertension; PAH: pulmonary arterial hypertension; GI: gastrointestinal involvement; JI: joint involvement; ACE2: angiotensin-converting-enyzme-2.